NCT04492553View on ClinicalTrials.gov

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Hypogonadism
Interventions
DRUG

AndroGel

Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.

Trial Locations (3)

2100

Copenhagen University Hospital, Copenhagen

2730

Herlev University Hospital, Herlev

4000

Zealand University Hospital, Roskilde

Sponsors

Collaborators (1)

Besins Healthcare
All Listed Sponsors
collaborator

Besins Healthcare

INDUSTRY

collaborator

Copenhagen University Hospital at Herlev

OTHER

collaborator

Zealand University Hospital

OTHER

lead

Lars Møller Pedersen

OTHER

NCT04492553 - Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality | Biotech Hunter | Biotech Hunter